KRAS and familial pancreatic carcinoma: STAT3 activation promotes the oncogenic phenotype of pancreatic cancer, and loss of STAT3 prevents pancreatic cancer development and progression in a mouse model of Kras-mediated pancreatic cancer [27], [28].